Skip to main content
Clinical Trials/EUCTR2008-003877-42-DK
EUCTR2008-003877-42-DK
Active, not recruiting
Phase 1

Relapse prevention in patients with major depression treated with electroconvulsive therapy using a fixed dose range of escitalopram compared to a fixed dose of nortriptyline (DUAG-7)A randomised controlled 6 month double-blind study - Relapse prevention with escitalopram or nortriptyline following ECT (DUAG-7)

Danish University Antidepressant Group (DUAG)0 sites300 target enrollmentOctober 28, 2008

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Danish University Antidepressant Group (DUAG)
Enrollment
300
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 28, 2008
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Danish University Antidepressant Group (DUAG)

Eligibility Criteria

Inclusion Criteria

  • Remission of depression after Electroconvulsive Therapy (ECT)
  • Age above 18
  • ECT course ended within the last 21 days
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Suicidality corresponding to more than a score of more than 3 on the Hamilton depressionsskale item 3 or if project participant or investigator cannot determine the level of suicidality.
  • Manic symptoms of a severety corresponding to a score of 15 or more on the Bech\-Rafaelsen Mania scale at inclusion and at any time during the study period.
  • Duration of current depressive episode of more than 2 years.
  • Participant is under coercive measures.
  • Dementia or any other known organic brain disease than is anticipated to influence the validity of the informed consent and compliance with the study.
  • Presence of known clinical important somatic diseases supposed to be problematic in relation to study procedures.
  • Epilepsia.
  • Cognitive deterioration caused by the Electroconvulsive therapy supposed to be problematic in relation to study procedures.
  • Schizophrenia, schizoaffektive disorder or other psychotic disorder without relation to actual depressive episdoe.
  • Bipolar I, Bipolar II or Rapid cy\-cling bipolar sygdom.

Outcomes

Primary Outcomes

Not specified

Similar Trials